{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:55:52Z","timestamp":1784919352315,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      To determine the diagnostic performance and clinical usefulness of\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) PET computerised tomography (CT) in detecting cardiac inflammation in patients with suspected cardiac sarcoidosis; and to explore the role of interval and correlative imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      A 10-year (2015\u20132024) retrospective observational study was conducted at our teaching hospital. 397\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scans performed in 296 patients with suspected or known cardiac sarcoidosis were reviewed. Assessment of diagnostic quality, patterns of myocardial and extracardiac FDG uptake, concordance with other modalities [cardiac MRI (CMR) and myocardial perfusion imaging (MPI)] were assessed. Separate subgroup analysis of patients undergoing repeat\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scans was conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Images of excellent diagnostic quality\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT were obtained in 365\/397 studies (91.9%). Cardiac inflammation was identified in 226 and scans were normal in 139 patients. Extracardiac sarcoidosis was present in 230 (63%) patients. MPI was abnormal in 50\/98 patients (51%) and CMR was abnormal in 88\/126 patients (70%). PET and MPI findings showed concordance in 53% patients but not considered significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.78). High concordance with CMR was noted in 85.7% patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). For treatment monitoring, follow-up\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scans accurately assessed disease status in 66\/70 patients (94.2%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We obtained excellent diagnostic quality of images in a high proportion of our patients (92%). Because of a high degree of concordance between\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT and CMR, we propose that either test can be used initially and the other test can be used in cases of clinical discordance. Interval\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scans are immensely useful for treatment response monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002108","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:00:16Z","timestamp":1768467616000},"page":"447-461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["18F-fluorodeoxyglucose PET computed tomography in cardiac sarcoidosis: lessons from a 10-year review"],"prefix":"10.1097","volume":"47","author":[{"given":"Vineet","family":"Pant","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muntasir Abo","family":"Al Hayja","sequence":"additional","affiliation":[{"name":"Cardiac Imaging, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobhan","family":"Vinjamuri","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mayocp.2015.10.024","article-title":"Epidemiology of Sarcoidosis 1946-2013: a population-based study.","volume":"91","author":"Ungprasert","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis.","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-0034-1376889","article-title":"Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.","volume":"35","author":"Lynch","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"R4-20260304","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.","volume":"119","author":"Perry","year":"1995","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.CIR.58.6.1204","article-title":"Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.","volume":"58","author":"Silverman","year":"1978","journal-title":"Circulation"},{"key":"R6-20260304","first-page":"178","article-title":"Sarcoidosis presenting as heart disease.","volume":"13","author":"Nelson","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2008.09.009","article-title":"Cardiac sarcoidosis.","volume":"157","author":"Kim","year":"2009","journal-title":"Am Heart J"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12350-017-1043-4","article-title":"Document Reading Group. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.","volume":"25","author":"Slart","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"R9-20260304","first-page":"50","article-title":"Cardiac sarcoidosis-state of the art review.","volume":"6","author":"Hulten","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","article-title":"ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.","volume":"23","author":"Dilsizian","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11886-013-0370-6","article-title":"18F-FDG PET\/CT for the assessment of myocardial sarcoidosis.","volume":"15","author":"Skali","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/RLU.0000000000000966","article-title":"MRI and FDG PET\/CT imaging manifestations of cardiac sarcoidosis.","volume":"40","author":"Lu","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R13-20260304","first-page":"35","article-title":"Cardiac sarcoidosis: the role of cardiac MRI and 18F-FDG-PET\/CT in the diagnosis and treatment follow-up.","volume":"30","author":"Al Hayja","year":"2023","journal-title":"Br J Cardiol"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00259-020-05066-5","article-title":"4Is Cardiovascular Imaging: a joint initiative of the European Association of Cardiovascular Imaging (EACVI); European Association of Nuclear Medicine (EANM). Procedural recommendations of cardiac PET\/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM.","volume":"48","author":"Slart","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2967\/jnumed.117.196287","article-title":"Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring.","volume":"58","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Med"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12350-016-0502-7","article-title":"Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation.","volume":"24","author":"Osborne","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/0972-3919.136559","article-title":"Effect of duration of fasting and diet on the myocardial uptake of F-18-2-fluoro-2-deoxyglucose (F-18 FDG) at rest.","volume":"29","author":"Kumar","year":"2014","journal-title":"Indian J Nucl Med"},{"key":"R18-20260304","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.21037\/tlcr-22-611","article-title":"Value of 18-fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG PET\/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study.","volume":"11","author":"Chen","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2967\/jnumed.112.104380","article-title":"The utility of 18F-FDG PET\/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.","volume":"53","author":"Sobic-Saranovic","year":"2012","journal-title":"J Nucl Med"},{"key":"R20-20260304","first-page":"123","article-title":"The role of positron emission tomography-computed tomography\/magnetic resonance imaging in the management of sarcoidosis patients.","volume":"17","author":"Promteangtrong","year":"2014","journal-title":"Hell J Nucl Med"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/hc0902.103432","article-title":"Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis.","volume":"105","author":"Takeda","year":"2002","journal-title":"Circulation"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"1286684","DOI":"10.3389\/fimmu.2023.1286684","article-title":"Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake.","volume":"14","author":"Frischknecht","year":"2023","journal-title":"Front Immunol"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/RLU.0000000000001124","article-title":"FDG PET\/CT evidence of effective treatment of cardiac sarcoidosis with adalimumab.","volume":"41","author":"Miller","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.","volume":"21","author":"Osborne","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"R25-20260304","first-page":"1989","article-title":"Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.","volume":"45","author":"Okumura","year":"2004","journal-title":"J Nucl Med"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehi180","article-title":"Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis.","volume":"26","author":"Ishimaru","year":"2005","journal-title":"Eur Heart J"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"e007030","DOI":"10.1161\/CIRCIMAGING.117.007030","article-title":"Complementary value of cardiac magnetic resonance imaging and positron emission tomography\/computed tomography in the assessment of cardiac sarcoidosis.","volume":"11","author":"Vita","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"e190140","DOI":"10.1148\/ryct.2020190140","article-title":"Utility of FDG PET and cardiac MRI in diagnosis and monitoring of immunosuppressive treatment in cardiac sarcoidosis.","volume":"2","author":"Coulden","year":"2020","journal-title":"Radiol Cardiothorac Imaging"},{"key":"R29-20260304","first-page":"1030","article-title":"Identification of cardiac sarcoidosis with (13)N-NH(3)\/(18)F-FDG PET.","volume":"44","author":"Yamagishi","year":"2003","journal-title":"J Nucl Med"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MCP.0b013e3283480d36","article-title":"Molecular imaging in sarcoidosis.","volume":"17","author":"Ma\u00f1\u00e1","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"e220292","DOI":"10.1148\/ryct.220292","article-title":"Combined FDG PET\/MRI versus standard-of-care imaging in the evaluation of cardiac sarcoidosis.","volume":"5","author":"Marschner","year":"2023","journal-title":"Radiol Cardiothorac Imaging"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41824-025-00263-7","article-title":"Emerging PET-radiotracers in cardiovascular, neuro-inflammation, lung and rheumatological diseases: a narrative review.","volume":"9","author":"Albano","year":"2025","journal-title":"EJNMMI Rep"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"101835","DOI":"10.1016\/j.nuclcard.2024.101835","article-title":"Potential application of 68Ga-FAPI PET\/CT for diagnosing cardiac sarcoidosis.","volume":"36","author":"Solanki","year":"2024","journal-title":"J Nucl Cardiol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:32Z","timestamp":1772607632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002108","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"2025-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}